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Abstract
Coagulation factor VIII (FVIII) is secreted as a heterodimer consisting of a heavy chain (HC) and a
light chain (LC), which can be expressed independently and reassociate with recovery of biological
activity. Because of the size limitation of adeno-associated virus (AAV) vectors, a strategy for
delivering the HC and LC separately has been developed. However, the FVIII HC is secreted 10–
100-fold less efficiently than the LC. In this study, we demonstrated that the F309S mutation and
enhanced B-domain glycosylations alone are not sufficient to improve FVIII HC secretion, which
suggested a role of the FVIII LC in regulating HC secretion. To characterize this role of the FVIII
LC, we compared FVIII HC secretion with and without the LC via post-translational protein trans-
splicing. As demonstrated in vitro, ligation of the LC to the HC significantly increased HC secretion.
Such HC secretion increases were also confirmed in vivo by hydrodynamic injection of FVIII intein
plasmids into hemophilia A mice. Moreover, similar enhancement of HC secretion can also be
observed when the LC is supplied in trans, which is probably due to the spontaneous association of
the HC and the LC in the secretion pathway. In sum, enhancing the secretion of the FVIII HC
polypeptide may require the proper association of the FVIII LC polypeptide in cis or in trans. These
results may be helpful in designing new strategies to improve FVIII gene delivery.
INTRODUCTION
Factor VIII (FVIII) plays a critical role in the coagulation cascade by accelerating the
conversion of factor X to factor Xa. Deficiency in FVIII activity is responsible for the bleeding
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disorder hemophilia A.1 The current treatment for hemophilia A in the developed countries is
intravenous infusion of plasma-derived or recombinant FVIII protein. Despite this treatment
being effective in controlling bleeding episodes, the requirement for frequent infusion, owing
to the short half-life of FVIII (8–12 hours), makes it inherently costly. Gene therapy has
emerged as an attractive strategy for the eventual cure of this disease.2,3 However, the progress
in delivering FVIII gene using one of the most promising viral vectors, adeno-associated virus
(AAV), has lagged behind the progress in delivering coagulation factor IX4–8 because of the
large size of FVIII complementary DNA approaching the packaging capacity of AAV.
Although a dual vector strategy delivering the FVIII heavy chain (HC) and light chain (LC)
separately9–11 circumvented the packaging limitation of AAV, it exhibited a severe “chain
imbalance” owing to the inefficient secretion of the FVIII HC, which rendered this approach
less efficient and effective. Therefore, understanding of the causes for limited FVIII secretion
is required to improve the results of this strategy.
Although FVIII and factor V share 40% sequence homology in the A and C domains, full-
length FVIII protein by itself is less efficient in terms of secretion than factor V.12–14 After
translation, FVIII is transported to the lumen of the endoplasmic reticulum (ER), where it
associates with several protein chaperones, including immunoglobin-binding protein (BiP),
calnexin, and calreticulin. The release of FVIII from BiP is an adenosine triphosphate–
dependent process, which is one of the main limiting factors for efficient FVIII secretion.
Calnexin and calreticulin enhance both FVIII secretion and degradation.12–14 In the ER, the
signal peptide is removed and oligosaccharides are added to the FVIII protein. Any mis-folded
protein is degraded in the ER, and the correctly processed FVIII molecules enter the Golgi
apparatus. LMAN1(ERGIC-53) is a chaperone protein in the ER–Golgi intermediate
compartment that is required for efficient FVIII and FV secretion.15 The oligosaccharide
content in the B domain can also affect FVIII secretion.16 Further studies found that the
inclusion of the first 226 amino acid residues in the B domain, containing six potential
asparagine-linked glycosylation sites, in B-domain-deleted FVIII (BDD-FVIII) increased its
secretion tenfold while maintaining the same levels of messenger RNA as BDD-FVIII.3,14,
17–19 Moreover, it has been reported that the combination of certain modifications in the FVIII
coding region can overcome these limitations and improve FVIII secretion 15- to 25-fold.3,
14 These modifications include (i) use of BDD.FVIII to increase the steady-state messenger
RNA levels, (ii) substitution of Phe at postion 309 with Ser in the A1 domain to reduce the
affinity to the ER chaperone BiP and the dependence on adenosine triphosphate for secretion,
and (iii) inclusion of six asparagine-linked oligosaccharides sites in BDD-FVIII to increase
ER to Golgi transport.
To investigate whether the secretion of the FVIII HC requires the LC in cis, we explored an
intein strategy that can ligate the LC to the HC before secretion. Inteins are the protein
equivalent of introns. They are excised from a precursor protein and the N- and C-terminal
sequences adjacent to an intein are rejoined with a peptide bond. Such an excise–rejoin reaction
of “protein splicing”20 is directly analogous to RNA splicing of introns. However, intein-
mediated protein splicing takes place post-translationally. The N- and C-terminal sequences
in the precursor protein are named N-extein and C-extein, respectively. A mature polypeptide
is formed when the exteins are ligated together after the inteins are removed. Although most
inteins are contiguous, there exists a special category of inteins in which the precursor proteins
come from two different genes.21 Those inteins are called “split inteins.” The two split intein
polypeptides, through their structural complementarity, can reassemble and catalyze a protein
trans-splicing reaction to produce a ligated polypeptide. The Ssp DnaB split intein was used
in this study.22,23
In the current study, we determined how the FVIII LC affected the secretion of the HC. Using
the novel protein trans-splicing reaction, we were able to compare the secretion of the FVIII
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HC with and without ligation of the LC. The results suggest that FVIII LCs are critical in
maintaining the proper configuration of HCs for secretion. Overall, our findings provide
valuable information on engineering FVIII protein for both protein therapy and gene therapy
of hemophilia A.
RESULTS
F309S and glycosylation modifications alone are not sufficient to improve FVIII HC secretion
The efficiency of FVIII secretion is limited by a number of factors, which include messenger
RNA instability, interaction with chaperones in the ER, and the requirement for the mannose-
binding lectin LMAN1 to facilitate ER to Golgi transport.24 F309S and partial B domain
sequences exhibited a dramatic enhancing effect on FVIII secretion. Because the FVIII HC is
poorly secreted when expressed alone, we hypothesized that incorporating the above
modifications into the HC moiety might improve the secretion efficiency of the FVIII HC. To
test this hypothesis, we constructed a variety of FVIII plasmids containing different regions of
the FVIII gene. As shown in Figure 1, Phe309Ser mutation and sequences of the B domain
containing the six glycosylation sites were incorporated into the FVIII coding region in the
expressing plasmid HC-N6. When the respective FVIII expression plasmids were transfected
into 293 cells in parallel with their controls, we observed that the FVIII HC was poorly secreted
into the medium 48 hours after transfection (Figure 2a and b). Surprisingly, there was no
improvement in the secretion of the FVIII HC even with the Phe309Ser mutation and additional
B domain sequences in the HC-N6 peptide (Figure 2a). Secretion of the modified HC in HC-
N6 was similar to secretion of the unmodified HC and was approximately 5–20-fold less than
secretion of BDD-FVIII. This result suggested that the missing LC might play an important
role in facilitating the secretion of the HC.
Intein strategy to add the LC polypeptide in trans
To further delineate the mechanism of FVIII secretion, we designed an intein strategy to study
the effects of the addition of the LC to the HC on the secretion of FVIII molecules. An
illustration of this strategy is shown in Figure 3a. In the expression plasmid HC-INT, a 153-
amino-acid DnaB N-intein was added to the C-terminal of the HC (Figure 1). In the expression
plasmid LC-INT, the coding region was arranged in the following configuration: the 19-amino-
acid FVIII signal peptide, the 36-amino-acid DnaB C-terminal intein, and the full sequence for
the FVIII LC. When these two plasmids were transfected together into 293 cells, a Western
blot of the cell lysate 48 hours after transfection using polyclonal antibodies against human
FVIII (Figure 3b) showed ligation products at the size of single-chain BDD-FVIII (lanes 1, 3,
7, and 8). In the cells transfected with expression plasmids for LC-INT or HC-INT alone, we
observed slightly higher intracellular levels of the LC with intein than of the HC with intein
(lanes 4 and 5). When these two plasmids were co-transfected at ratios of 9:1 or 1:1 of pLC-
INT to pHC-INT (lanes 6 and 7), the amount of the HC with intein was considerably less than
the amount of the LC polypeptide, which suggested that the majority of HC poly-peptides
probably were consumed in the trans-splicing reaction. In lane 8, the LC was probably
consumed close to completion, and the HC was in excess supply. Because the ligated FVIII
molecules can be secreted, the intensity of the bands corresponding to the single-chain BDD-
FVIII may not reflect the amount of single-chain FVIII generated through ligation. The amount
of secreted FVIII was analyzed in more detail in later experiments. On the basis of consumed
protein-splicing substrates, the results suggested that intein can mediate an efficient
intracellular FVIII ligation reaction that resulted in the addition of the LC to the HC before
FVIII secretion.
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LC improves HC secretion
We next examined whether the addition of the LC through a trans-splicing reaction could lead
to improvement in HC secretion. After the plasmids expressing HC-N6-INT and LC-INT had
been co-transfected into 293 cells in parallel with positive and negative controls, FVIII antigen
levels in the medium and in the cell lysates were analyzed by enzyme-linked immunosorbent
assay (ELISA). We employed the ratio of secreted FVIII to intracellular FVIII as an index for
secretion efficiency. As shown in Figure 4, the LC showed a much higher secretion efficiency
index. The amount of the FVIII LC expressed from the LC-INT plasmid and secreted in the
medium was 18 times more than that in the cytoplasm. In contrast, the HC polypeptide was
scarcely secreted, even though the HC-N6-INT expression vector included six glycosylation
sites and the F309S mutation. When the LC-INT expression plasmid was included in the
transfection, the expressed FVIII LC would go through the same secretion pathway as the HC
fragment and undergo the splicing reaction. The addition of the LC to the HC improved the
secretion of the HC to the level of BDD-FVIII secretion, though not to the level of FVIII LC
secretion. This result suggested that the LC was critical in promoting FVIII HC secretion and
explained why the HC by itself did not secrete efficiently.
Additional evidence supporting the hypothesis that the FVIII LC facilitates HC secretion is
presented in Figure 5. This experiment showed the amount of the HC secreted in medium with
or without the LC in cis. HC secretion was improved when HC-INT was co-transfected with
LC-INT, but still at a lower level than that of BDD-FVIII. However, additional B domain
sequences with six glycosylation sites and F309S mutation had enhancing effects when the LC
sequence was ligated to the modified HC. Although we did not observe a fivefold to tenfold
expression as reported elsewhere,14 HC-N6 consistently outperformed BDD-FVIII in
secretion in all repeated experiments.
To evaluate whether the LC can enhance FVIII HC intein polypeptide secretion in trans, we
constructed a plasmid pLC (Figure 1) that expresses a functional LC without intein. The LC
fragment from this plasmid would not be ligated to the expressed HC intein. As shown in Figure
6, the mere presence of the LC during the secretion process had no influence on HC-INT or
HC-N6-INT secretion. However, co-transfection of HC+LC, HC-N6+LC into 293 cells
showed a different result (Figure 6). The LC efficiently improved HC secretion even in
trans, although the level remained lower than that for BDD-FVIII. In contrast, HC-N6 secretion
was improved very little in the presence of the LC. This suggested that the additional B domain
sequence attached to the HC polypeptide alone had a negative effect on the interaction of the
HC with the LC. Therefore, the enhancing effect of the LC on HC secretion may depend upon
the substrates. Only FVIII HC molecules with proper interaction with the LC can be enhanced
in secretion.
The FVIII LC augmented FVIII HC secretion in vivo
To examine whether the FVIII LC could facilitate HC secretion in vivo, expression plasmid
pHC-INT, pLC-INT, or pHC-INT+ pLC-INT was introduced into the livers of hemophilia A
mice by hydrodynamic injection. Plasmid pCMV-FVIII, which expresses fully functional
BDD-FVIII, was included as a positive control. Twenty-four hours later, mouse plasma was
collected. Expression of circulating FVIII was determined by one-stage activated partial
thromboplastin time assay. The results are shown in Figure 7a. ELISA for human FVIII was
performed using a sheep anti-human FVIII as capture antibody and horseradish peroxidase–
conjugated polyclonal antibody as detection antibody (Figure 7b). As shown in Figure 7a, the
control groups injected with pLC-INT alone or pHC-INT alone did not show any clotting
activity. However, when these two plasmids were injected together, they produced a very high
level of FVIII clotting activity, reaching 50% of the level in the positive control group receiving
BDD-FVIII-expressing plasmid. In Figure 7b, the different levels of FVIII antigen secreted by
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these constructs are shown. Although the clotting activities differed dramatically among
pCMV-FVIII, pHC-INT+pLC-INT, and pLC-INT (LC) injections, there was not much
difference at the protein levels. This result suggests that 50% of FVIII proteins expressed
though intein-mediated ligation were active and contained the FVIII HC. It confirms that
restoration of the FVIII LC to the HC polypeptide can significantly increase the secretion of
functional FVIII protein.
DISCUSSION
FVIII is a protein that secretes inefficiently compared with similar proteins such as factor V.
1,13 Despite the overall low efficiency of secretion of single-chain FVIII or B-domain-deleted
FVIII protein compared with factor V, the HC and the LC polypeptides maintain a 1:1
stoichiometry. This suggests that the FVIII HC and LC must have overcome the secretion
hurdle together. Owing to the limited packaging capacity of AAV vectors, splitting FVIII
coding sequences into two AAV vectors is a practical approach to gene therapy.9–11 We think
this approach is particularly valuable for therapy of hemophilia A using recombinant AAV
vectors. Previous studies have shown that a major problem associated with this approach is
chain imbalance,9–11 which is at least partially attributable to inefficient secretion of the HC
not in association with the LC. Such chain imbalance not only decreases the amount of active
FVIII protein in circulation but also may destabilize the host cells and induce apoptosis.25 Our
results confirmed that FVIII HC secretion was almost two logs less efficient than LC secretion.
10 This biologically inherent discrepancy can scarcely be solved by manipulating promoters
and vector doses.
Previous studies have pointed out that the interactions between cellular chaperones and
elements in the FVIII HC limit FVIII secretion.3,13–15 Although there is a difference between
full-length FVIII and B-domain-deleted FVIII at the transcription level, we did not observe
significant differences between the HC and LC expression vectors at the transcription level
using quantitative real-time polymerase chain reaction (data not shown). In Figure 3, the
Western blot analysis of HC and LC polypeptides shows that the intracellular level of the HC
is about onefold to twofold lower than that of the LC. Thus, the biosynthesis of the HC is
unlikely to be the main factor that causes the dramatic difference between the levels of the
secreted FVIII LC and HC. The current perception is that secretion is the main hurdle to
obtaining a high level of FVIII or the FVIII HC in plasma. So far it is unclear why the HC is
so defective in terms of secretion. To improve FVIII secretion and solve the chain imbalance
issue, we took advantage of the success of FVIII bio-engineering, which showed promise not
only in improving FVIII functions, including half-life and stability, but also in reducing
antigenicity and improving FVIII secretion and production.26,27 The engineered B-domain-
deleted FVIII has been commercially available to hemophilia patients. Pipe’s group recently
showed that the F309S modification and the addition of up to six glycosylation sites in the B
domain could improve FVIII secretion by almost 20-fold.3,14 However, such modifications
did not have similar effects in terms of improving FVIII HC secretion (Figure 2). One possible
explanation is that the FVIII HC alone assumes a different configuration and folds improperly
without the FVIII LC in the ER or the Golgi apparatus. Therefore, the FVIII HC alone does
not follow the same pathway for secretion as intact single-chain FVIII molecules with the LC
moiety. This leads to the intracellular retention of the FVIII HC and eventual degradation of
FVIII protein. The results in Figure 4 support this hypothesis.
In this study, we successfully introduced intein as a tool to study the mechanism of FVIII
secretion. As an auto-catalytic reaction, intein-mediated trans-splicing avoided any
requirement for other cellular enzymes and co-factors.20 The accurate and efficient intein-
mediated trans-splicing reaction allowed us to compare the secretion of the HC alone and the
HC joined with the LC in the ER or the Golgi apparatus. The role of the FVIII LC in cis, along
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with the HC, during FVIII heavy secretion highlighted a serious defect in the expression of
FVIII using the dual-vector strategy. The demonstration of intein-mediated seamless
regeneration of FVIII protein in this study could offer an alternative strategy for the dual-vector
approach to the delivery of the FVIII gene using small gene transfer vectors such as AAV
vectors. Using this strategy, one vector could encode the first half of the FVIII gene and the
second vector could encode the LC fragment. This new scheme may allow the FVIII LC to be
attached to the HC polypeptide before secretion. The in vivo testing in Figure 7a using
hydrodynamic injection showed 50% functional FVIII using this method, as compared with
single-chain FVIII molecules, which suggested that this strategy warrants further study for
human gene therapy.
It is worth noting that the LC was able to enhance HC secretion in trans (Figure 6). The co-
transfection of the HC and the LC greatly improved the amount of the HC detected. An
alternative explanation is that the LC may also affect the HC’s stability (half-life) and rate of
synthesis. It has been reported that vWF increases FVIII half-life in vivo. Whether the LC has
similar effects remain unclear, especially in vitro. The assays employed in this study
demonstrated that mainly stable (ELISA) and functional FVIII was secreted (activated partial
thromboplastin time assay). In contrast, HC-N6, HC-INT exhibited little or no ability to
enhance secretion by the LC, which suggests that additional sequences in the HC, either native
FVIII amino acids or foreign sequences, may have altered the ability of the FVIII HC to interact
with the LC. This may imply that an HC molecule with enhanced interaction with the LC will
be a better choice for gene therapy.
FVIII secretion follows a very delicate pathway.13 Mutations and modifications in either the
HC or the LC could easily disrupt the interactions between the HC and the LC and therefore
reduce the enhancing effects of the LC on HC secretion. As shown in Figure 6, the LC did not
show an enhancing effect on HC-INT, HC-N6, and HC-N6-INT, as it did on the HC. One
possibility is that the additional sequence after the HC, whether it is intein or the native B
domain sequence, had an inhibitory effect on the interactions between the HC and the LC. The
enhancing effect in cis (LC-INT+HC-N6-INT) suggested that the B domain sequence did not
inhibit LC and HC interaction per se. The trans-splicing reaction may have altered the
configuration of the LC and HC complex. Thus, it is not surprising that the same B domain
sequences could have an inhibitory effect on secretion with the LC in trans while improving
FVIII secretion with the LC in cis (Figure 6). This result demonstrated that the enhancing
effects of the LC will depend on the type of HC molecules. By the same token, a single-point
mutation in the LC may also be able to disrupt FVIII folding and secretion. Previous studies
have shown that missense mutations in the C2 domain affected intracellular protein trafficking.
13,28 Although we did not construct many mutants to study this, the point mutations in the
human hemophilia A mutation database strongly support this hypothesis.29,30 In this database,
point mutations are scattered almost evenly throughout the whole FVIII LC. For example,
L1756V, G1760R, A1779P, S1888R, R1941Stop, and many other mutations led to less than
1% of FVIII antigen being detected in the patients. All these data point to the inevitable
conclusion that a proper LC is essential for efficient FVIII secretion. Proper utilization of the
enhancing effect of the LC would greatly affect the efficiency of FVIII delivery.
We demonstrated the enhancing effect of the FVIII LC on the secretion of the HC both in cis
and in trans. This information will be useful for designing future strategies for split delivery
of FVIII. To take advantage of either in cis and in trans enhancing effects requires both LC
and HC vectors to be presented in the same cells. Thus, highly efficient AAV vectors that can
carry both vectors equally into every cell will be desirable. Because the trans effect of the LC
on HC secretion was at a similar level as in cis, it makes sense to emphasize novel HC or LC
molecules with better enhancing effects rather than to introduce an intein, albeit small, to
complicate immune responses to the gene delivery in the host tissues or organs.
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FVIII expression plasmids construction
Human FVIII complementary DNA was used in all expression constructs in this study. The
expression of FVIII was directed by either a cytomegalovirus promoter (CMV) or a human β-
actin promoter with a CMV enhancer (CB).31 For direct comparisons in the experiments
performed in this study, all constructs were under the same promoter. The intein sequence was
derived from the previously characterized Ssp DnaB split intein.22,23 The pCMV-HC-INT
and pCMV-LC-INT plasmids were constructed by fusing appropriate fragments of the human
FVIII complementary DNA and the intein coding sequence and inserting the fusion gene in
the previously characterized pXX expression vector.32 The fusion gene of pCMV-HC-INT
encodes a fusion protein consisting of the first 779 amino acids of FVIII (including its 19-
amino-acid signal peptide), a 3-amino-acid Glu-Ser-Gly linker, and the first 106 amino acids
of the intein. The fusion gene of pCMV-LC-INT encodes a fusion protein consisting of the 19-
amino-acid signal peptide of FVIII, the last 50 amino acids of the intein, a 3-amino-acid Ser-
Ile-Glu linker, and the last 693 amino acids of FVIII. The plasmids pCB-HC-INT and pCB-
LC-INT were made by replacing the promoters in pCMV-HC-INT and pCMV-LC-INT with
a CB promoter. The plasmids expressing human FVIII HC (pCMV-HC, pCB-HC) and LC
(pCMV-LC, pCB-LC) were constructed by replacing the promoters in plasmids of pAAV-
hFVIII-HC and pAAV-hFVIII-LC with a CMV promoter or a CB promoter.9,10 The plasmid
pHC-N6 was constructed by replacing the HC fragment in pCB-HC or pCMV-HC with similar
fragments with six glycosylation sites from F309S/226aa/N6.14 The plasmid pHC-N6-INT
was similarly derived from pHC-INT.
Tissue culture and transfection
HEK 293 and COS cells were purchased from the American Type Culture Collection
(Manassas, VA) and cultured in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad,
CA) with 10% fetal bovine serum (HyClone, Logan, UT), penicillin (100 U/ml) and
streptomycin (Invitrogen, Carlsbad, CA) (100 μg/ml) at 37 °C in a humid environment supplied
with 5% CO2. Transfections were carried out using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) following the manufacturer’s instructions. Alternatively, a transfection procedure using
calcium phosphate precipitation was carried out as described previously.8,33 After
transfection, the cells were grown for 12–24 hours in Dulbecco’s modified Eagle’s medium
with 10% fetal bovine serum to minimize cell death. The cells were then maintained in OPTI-
MEM (Invitrogen, Carlsbad, CA) medium for 24–72 hours before the medium was collected
and the secreted FVIII antigens were analyzed. For direct comparison, a green fluorescent
protein expression plasmid was also included in the transfection mix to ensure similar
transfection efficiency. We used both COS cells and 293 cells for our experiments. After 293
cells were confirmed to produce similar results to COS cells, most experiments were carried
out using 293 cells.
Animal procedures
Exon 16 FVIII knock-out mice were obtained from Dr. Haig Kazazian (University of
Pennsylvania).8,33 All mice were housed in a specific pathogen-free environment with normal
diet. All surgical procedures involving mice were in accordance with Institutional Animal Care
and Use Committee guidelines under approved protocols at The Children’s Hospital of
Philadelphia.
For hydrodynamic injection, animals were injected via the tail vein with 2.0 ml saline
containing 200 μg column-purified plasmids in 5–10 seconds.34,35 The animals were allowed
to recover before being returned to the cages. Blood was collected at 24–48 hours after
hydrodynamic injection by tail clip using sodium citrate as an anticoagulant at a final
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concentration of 0.38% (wt/vol). The blood samples were then centrifuged at 4 °C for 10
minutes at 9,000 rpm in a microcentrifuge. The plasmas were then collected and used for FVIII
assays.
Quantitative analysis of FVIII antigen
FVIII-HC and FVIII-LC antigen were determined using chain-specific ELISAs. For the human
FVIII ELISA, matched-pair antibody sets for human FVIII antigen were purchased from
Enzyme Research Laboratories (South Bend, IN). Both detection and capture antibodies were
sheep anti-human FVIII immunoglobulin G. The linear range of this assay is from 3 to 100%
reference human FVIII as determined by the manufacturer. For human HC–specific ELISA,
Nunc Maxisorp (Nalge Nunc International, Rochester, NY) plates were coated with 2 μg/ml
HC-specific monoclonal antibody ESH5 (American Diagnostica, Greenwich, CT). Samples
and standards were diluted in OPTI-MEM (Invitrogen, Carlsbad, CA). Samples and standards
(100 μl/well) were incubated at room temperature for 2 hours. After washing, a horseradish
peroxidase–conjugated sheep anti-human FVIII antibody F8C-EIA-D (100 μl/well, 2 μg/ml;
Affinity Biologicals, Ancaster, Canada) was added, and the plates were incubated for 2 hours
at room temperature. After a final wash the antigen was detected using 2,2′-azino-bis-[3-
ethylbenzthiazoline-6-sulfonic acid] substrate (Roche, Germany) and the absorbance read at
405 nm. The hFVIII-LC ELISA was performed similarly, with the following changes: the
capture antibody was 2 μg/ml monoclonal antibody to human FVIII LC N55195M (Biodesign
International, Saco, ME); the detection antibody was 26 μg/ml sheep antihuman FVIII antibody
from Haematologic Technologies (Essex Junction, VT), followed by 2 μg/ml horseradish per-
oxidase–conjugated rabbit anti-sheep immunoglobulin G (H+L) from Bio-Rad Laboratories
(Hercules, CA). For all ELISAs, the standard used was Refacto (Genetics Institute, Cambridge,
MA), recombinant BDD-FVIII.
Biologically active FVIII in media and plasma was measured using the activated partial
thromboplastin time assay as previously described.8,9,33 Refacto (Genetics Institute,
Cambridge, MA) was used as the standard.
To measure the intracellular level of FVIII antigen, the cells were harvested from tissue culture
dishes. The cell pellets after centrifugation were re-suspended in phosphate-buffered saline
with protease inhibitors and sonicated ten times in a Branson Sonifier (Branson Ultrasonics
Corporation, Danbury, CT) under level two with 50% output. Then the samples were
centrifuged for 5 minutes at 12,000g to remove cell debris. The supernatant was collected and
an equal amount (i.e., 100 μ) of supernatant for each sample was used for ELISA following
the procedure described above.
Western blot analysis of FVIII
To analyze intracellular FVIII antigen, cells transfected with FVIII plasmids were lysed with
radioimmunoprecipitation buffer (50 mmol/l Tris–HCl pH 7.4,150 mmol/l NaCl, 1 mmol/l
phenylmethylsulphonyl fluoride,1 mmol/l EDTA, 1% Triton X-100, 1% sodium dodecyl
sulfate). After sonication to break the genomic DNA, an equal volume of 2× sample buffer
was added and boiled for 2 minutes. The resulting samples were analyzed using 6% or 4–12%
gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis gels and transferred to
nitrocellulose membrane for Western blotting. After the membrane was blocked overnight in
phosphate-buffered saline/10% skim milk powder/0.3% Tween-20, a sheep anti-hFVIII
antibody, SAF8C (1:1,000 dilution; Enzyme Research Laboratories, IN), was added and the
sample was incubated for 1 hour at room temperature. The membrane was washed, incubated
with a rabbit anti-sheep antibody (1:2,000 dilution; Bio-Rad Laboratories (Hercules, CA)), and
developed using an enhanced chemiluminescent substrate (Amersham-Pharmacia Biotech,
Piscataway, NJ).
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Figure 1. Schematic representation of factor VIII (FVIII) and derivatives in this study
The arrows represent the signal peptide. The domains and the positions of amino acids relative
to the full-chain FVIII peptide are identified in the figure. BDD-FVIII, B-domain-deleted
FVIII; HC, heavy chain; INT, intein sequence; LC, light chain.
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Figure 2. Analysis of factor VIII (FVIII) heavy chain (HC) secretion
Plasmids expressing B-domain-deleted (BDD)-FVIII, HC, HC-N6, the light chain (LC), and
mock control were transfected into 293 cells by calcium phosphate precipitation in triplicate.
FVIII HC and LC secretion at 48 hours after transfection was measured. (a) Enzyme-linked
immunosorbent assay (ELISA) for the HC only. (b) ELISA for the LC only. The SD is shown
in the figure.
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Figure 3. Intein-mediated factor VIII (FVIII) light chain ligation
(a) An illustration of the intein strategy. The top box with the dotted line shows the DNA
manipulation procedures. The bottom box with the solid line shows the protein ligation
reactions. (b) Western blot of intein-mediated ligation of the heavy chain (HC) and light chain
(LC). Plasmids pCMV-BDD-FVIII, pCMV-HC-INT, pCMV-LC-INT, and pCMV-HC-INT
+pCMV-LC-INT at ratios of 9:1, 1:1, and 1:9 were transfected into COS cells using
Lipofectamine. At 36 hours after transfection, cell lysates were prepared for Western blot
analysis (4–12% gradient polyacrylamide gel electrophoresis gel). The blot was probed with
a sheep anti-human FVIII polyclonal antibody (Haematologic Technologies, VT). Lanes are:
1: ReFacto FVIII protein; 2: mock transfection; 3: pCMV-BDD-FVIII; 4: pCMV-LC-INT; 5:
pCMV-HC-INT; 6: pCMV-LC-INT+pCMV-HC-INT at a ratio of 9:1; 7: pCMV-LC-INT
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+pCMV-HC-INT at 1:1; 8: pCMV-LC-INT+pCMV-HC-INT at 1:9. cDNA, complementary
DNA; SC: single-chain B-domain deleted (BDD)-FVIII protein.
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Figure 4. The effects of the light chain (LC) on the secretion efficiency index
The plasmids pCB-LC-INT, pCB-HC-N6-INT, pCB-BDD-FVIII, and pCB-LC-INT+pCB-
HC-N6-INT (1:1) were transfected into 293 cells. The amount of total FVIII antigen in the
medium and inside the cells was measured by enzyme-linked immunosorbent assay at 48 hours
after transfection. The secretion efficiency was defined as the ratio of factor VIII (FVIII) in
the medium to FVIII in the cells and is presented as a bar graph. BDD-FVIII, B-domain-deleted
FVIII; HC, heavy chain; INT, intein sequence.
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Figure 5. The light chain (LC) facilitates heavy chain (HC) secretion in cis
The plasmids pCB-BDD-FVIII, pCB-HC-INT, pCB-HC-INT+pCB-LC-INT (1:1), pCB-HC-
N6-INT, pCB-HC-N6-INT+pCB-LC-INT (1:1), pCB-LC-INT, and mock control were
transfected into 293 cells and assayed 48 hours after transfection. The secreted factor VIII
(FVIII) HC was measured by enzyme-linked immunosorbent assay. The y-axes show the
concentration of FVIII HC in ng/ml. Transfections were performed in quadruplicate to obtain
average values. The SD is shown in the figure. BDD-FVIII, B-domain-deleted FVIII; INT,
intein sequence.
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Figure 6. The light chain (LC) may affect heavy chain (HC) secretion in trans
The plasmids pCB-FVIII, pCB-HC-INT, pCB-HC-INT+pCB-LC (1:1), pCB-HC-N6-INT,
pCB-LC+pCB-HC-N6-INT (1:1), pCB-HC, pCB-HC+pCB-LC (1:1), pCB-HC-N6, pCB-LC
+pCB-HC-N6 (1:1), and mock control were transfected into 293 cells and assayed 48 hours
after transfection. The secreted factor VIII (FVIII) HC was measured by enzyme-linked
immunosorbent assay. The y-axes show the concentration of FVIII HC in ng/ml. Transfections
were performed in quadruplicate to obtain average values. The SD is shown in the figure. BDD-
FVIII, B-domain-deleted FVIII; INT, intein sequence.
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Figure 7. The light chain (LC) enhances heavy chain (HC) secretion in vivo
Plasmids pCMV-BDD-FVIII, pCMV-HC-INT, pCMV-LC-INT, and pCMV-HC-INT
+pCMV-LC-INT were administered into hemophilia A mice by hydrodynamic injection (n =
3 or 4). Each mouse received 200 μg DNA. DNA was diluted in 2.0 ml saline and injected into
mice by tail vein injection. The mouse plasma was collected 24 hours after DNA
administration. (a) Functional factor VIII (FVIII) units converted from activated partial
thromboplastin time assay. (b) The FVIII antigen (HC and LC) in the plasma was measured
by ELISA. The SD is shown in the figure. BDD-FVIII, B-domain-deleted FVIII; INT, intein
sequence; LC, light chain.
Chen et al. Page 18
Mol Ther. Author manuscript; available in PMC 2008 December 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
